C-KOPTDialectic Therapeutics
protein degradation, BCL-XL, targeted oncology
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KOPT
C-KOPTC-KOPTprotein degradation, BCL-XL, targeted oncology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
A Phase 1, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Subjects with Relapsed or Refractory Malignancies
Journey Through Classical Education: Homeschooling with Purpose and Passion | 228 - Teach Them Diligently About About Us Our History Statement of Faith Gospel Vision FAQs Invite David or Leslie Nunnery To Speak Contact Us Events 2027 Registration Exhibitors Exhibitor Registration Exhibitor Information Media Kit Speakers Refer A Friend Sponsors Membership Heart School Heart School Paperback Book Heart School Digital Book Heart School Audio Book Heart School Parenting Intensive Podcast Homeschool Family Favorites Financial Stewardship Weekly Newsletter Blog Store Bookstore Convention Store Sign … to trust themselves and walk in faith while homeschooling Podcast Sponsor: The AWARD WINNING CSB Explorer Bible for Kids helps kids place God’s Word in the middle of God’s world. Within its engaging, full-color pages, kids will interact with the people, places, and things of the Bible and God’s creation. Fascinating images, illustrations, timelines, and study helps show archeological evidence, introduce key characters, explain new concepts, and help kids experience the wonde … cational videos, discussion questions, and activity pages to life, helping kids apply key truths of the Bible to real world experiences. Click HERE to find out more. We want to hear from you! Submit your podcast questions, topic suggestions, and guest requests and help us make the Teach Them Diligently Podcast great. Name * First Last Email * Question / Topic / Request * CAPTCHA Δ Leslie Nunnery Leslie Nunnery is a homeschool mother, author, and speaker with a heart for … books and resources that help families engage meaningfully with God’s Word and apply those truths directly to family life. Through her teaching, she gently calls parents back to the Lord as their first priority, equipping them to lead their homes with intention, prayer, and a vision that reaches far beyond the school years. Leave a Reply Cancel reply You must be logged in to post a comment. Search for: My Dashboard My Account My Orders My Tickets My Groups My Courses Message
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.4 %���� 1 0 obj > endobj 7 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > endobj … B� ]�R��Þ��e��ʘ裈ֻs�B�Kmޮ�r�* gz+ � ��!��[ E4P@�r �e�u�dQF� s����O�!��D?Wb��RFP�Y�/�iw��F���2 ʓ q�@��� �S�uM(i4Ո����|�� ��e}N[�MG�N+J=�`����$i � U$���1o'�� ���EK ;������ ����nt2 D���K$>��5�D&�Iq������-P~= ��f�| ��������[['��&$�� ��xج�]}�m��;/�� endstream endobj 108 0 obj > endobj 109 0 obj > stream x��]]�ܶ}�_1�2II�À��}H�4� �I��I���� ���3Ǽ����Y��I�3�H�~�{�{���vͮ�}��ӏv��w���aol�;�a�h��8ڝ�M��㧻�������;�� ���w� ��w��y���_���_�^}�v���������w�����O
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
„Dialectic“-Podcast – Apple Podcasts Suchen Startseite Neu Top-Charts Suchen Dialectic Jackson Dahl 0,0 (0) Wirtschaft Wöchentlich Conversational portraits of original people, across technology, media, business, and creativity. By Jackson Dahl. Neueste Folge Folgen Folgen 18. Juni Jasmine Sun: Close Enough to See Clearly Jasmine Sun (Substack, X, LinkedIn) is an independent writer and journalist. She is a contributing writer for The Atlantic and also writes for other major publications, like The New York Times. She previously led core product at Substack. Jasmine focuses on Silicon Valley and … early book-length) piece on Peter Thiel’s legendary investment outfit, Founders Fund, and profiled Microsoft’s Satya Nadella. I spoke to Mario about stories and the truths they hold or reveal. He is a writer first, and it shows in his prose, style, and depth. We also discussed the evolution of The Generalist’s content and business model, both of which he has experimented with ruthlessly. The subscription counts 160,000+ readers / listeners and is currently ranked as the #7 be
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Warren Feld - FLUENCY IN JEWELRY DESIGN: Sensation of... Facebook Log In Warren Feld's Post Warren Feld September 22, 2025 · Shared with Public FLUENCY IN JEWELRY DESIGN: Sensation of Jewelry as DIALECTIC SENSATION OF JEWELRY AS DIALECTIC DIALECTIC: Jewelry As Interaction and Shared Understandings. Jewelry is a two-way street. It is a way to create, confirm and retain connections. At its very core, it is interactive and communicative. It is more an action than an object. Jewelry can start a conversation. Jewelry encapsulates a very public, ongoing matrix of choices and interactions among
Dialectic Capital Delivers Letter to Covisint Board Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overview T … rategy. You said we were reasonable, and even effectively said yes to our proposal, which was later rejected. If you are going to put all your eggs in one basket, we want to make sure it's the right basket. As we detailed in our June 2 nd letter, we engaged in discussions with the Company because we were alarmed by the fact-pattern leading up to the Q4 earnings release, in which the Company decided to schedule the earnings call days after the deadline for n … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Dialectic Therapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & … $32.6M over 8 rounds . Dialectic Therapeutics's latest funding round was a Grant for $14.4M on August 20, 2021 . Date Round Amount Investors Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. Revenue Sources 8/20/2021 Grant $14.4M Cancer Prevention and Research Institute of Texas $XXM 0 FY undefined 1 2/11/2021 Debt - II $XXM Subscribe to see more $XXM 0 FY undefined 10 … 0 FY undefined 10 Date 8/20/2021 2/11/2021 12/29/2020 10/6/2020 2/26/2020 Round Grant Debt - II Debt Unattributed - II Seed Amount $14.4M $XXM $XXM $XXM $XXM Investors Cancer Prevention and Research Institute of Texas Subscribe to see more Subscribe to see more Subscribe to see more Subscribe to see more Valuation $XXM $XXM $XXM $XXM $XXM Revenue 0 FY undefined 0 FY undefined 0 FY undefined 0 FY undefined 0 FY undefined Sources 1 10 10 10 10 Learn more by requesting a demo Di … ntion and Research Institute of Texas invested in Dialectic Therapeutics's Grant funding round . First funding Last Funding Investor Rounds Board Seats Type Location 2/26/2020 8/20/2021 Cancer Prevention and Research Institute of Texas 2 Seed , Grant (2021) Government Texas 00/00/0000 00/00/0000 University of Florida Subscribe to see more Academic/University Florida JDH Investment Management Subscribe to see more Venture Capital Texas UF Innovate | Accelerate Subscribe t … y of Florida JDH Investment Management UF Innovate | Accelerate Rounds 2 Seed , Grant (2021) Subscribe to see more Subscribe to see more Subscribe to see more Board Seats Type Government Academic/University Venture Capital Incubator/Accelerator Location Texas Florida Texas Florida Learn more by requesting a demo Loading... 498 Seventh Avenue 12th
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
%PDF-1.4 %���� 1 0 obj > endobj 6 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > endobj … ���ݕ�z9!V]e(`��:��g( �/�$�a�� ggh$�� ���hN窩�| #>�MN,���_Ncj{��92�]�?rfP��^C��8K��x���w ]!����l��d� �%h�D4'A�FD�����ۻM���}�����kC����˷��?}+���>����h������:��F�m��n��'���|ZfS�:�)ϔ}�(�|W�� ��T�h� ����5��>�� �Ʒ8���� � ��L��7��6�p��c�1��b �c�����۟�;��.*sEӻe]u�����n"�oG1?�dh��e۬���p�X��(q�A>ܮ��A7F �j��nY ���Wh������{L������y}��#89� endstream endobj 1277 0 obj > endobj 1278 0 obj > stream x��]Y� 7�~�_����}��%��l 5X��c� ��_d]�ί3"��]����#U$�G
The Fibrolamellar Cancer Foundation establishes partnership with Dialectic Therapeutics | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Scand30: 1 Object, Nordic War Stories and the forgotten ‘freedom fighter’ armband of 1945 w/ Marianne Stecher-Hansen | National Nordic Museum Skip to main content Control Panel Text Size: A A A National Nordic Museum Text Size: A A A Buy Tickets Become a Member Hours & Directions Search Submit Search Visit Visit Menu Buy Tickets What to See and Do Tickets Hours & Directions Getting to the Museum Accessibility Group Tours What's in the Neighborhood Tips for Your Visit Exhibitions & Events Exhibitions & Events Menu Exhibitions Events Calendar Northern Lights Auktion Nordic I … re! Email Address * Subscribe Facebook Instagram YouTube LinkedIn TikTok Search Submit Search Visit Visit Menu What to See and Do Tickets Hours & Directions Getting to the Museum Accessibility Group Tours What's in the Neighborhood Tips for Your Visit Exhibitions & Events Exhibitions & Events Menu Exhibitions Events Calendar Northern Lights Auktion Nordic Innovation Summit Julefest Shop & Eat Shop & Eat Menu Shop Museum Store Freya Cafe Join & Sup
Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216 Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Over … urces Blog Journalists RSS Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216 News provided by Dialectic Therapeutics Mar 03, 2021, 09:30 ET Share this article Share to X Share this article Share to X DALLAS , March 3, 2021 /PRNewswire/ -- Dialectic Therapeutics, Inc. (Dialectic ® ), a Texas -based biotechnology company focused on creating innovative new technologies to treat cance … gradation (APTaD™) technology. In pre-clinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy. "FDA clearance of our IND represents an important milestone as it transitions Dialectic into a clinical-stage company and further advances us toward … the pre-clinical development of DT2216 have also been supported through a Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT). For more information regarding Dialectic, please visit www.dtsciences.com. Dialectic is a registered trademark of Dialectic Therapeutics, Inc. Contact: Josh Sills , EVP of Operations email: [email protected] SOURCE Dialectic Therapeutics Related Links www.dtsciences.com 21 % more … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS
DIALECTIC: A Multi-Agent System for Startup Evaluation 1 Introduction 2 Related Work 3 DIALECTIC 3.1 Fact Collection Phase 3.2 Reasoning Phase 3.3 Decision-Making Phase 3.4 Hyperparameters & Implementation 4 Evaluation Setup Dependent variable Independent variables Baselines Dataset split Metrics 5 Results 5.1 Hyperparameter Optimization 5.2 Predictive Performance Against Baselines 5.3 Evidence Utilization 6 Conclusion A Dataset Creation A.1 Preventing Look-Ahead Bias Cutoff date A.2 Data Preprocessing B DIALECTIC Design Details B.1 Seed Questions B.2 Generating Question Trees B.3 Evaluati … cision funnel due to limited investor bandwidth. This shift allows investors to apply iterative reasoning earlier in the process, improving both diligence quality and screening efficiency. 2 Related Work Prior studies propose different machine learning approaches to predict startup outcomes, drawing on public data sources such as Crunchbase (Arroyo et al., 2019 ; Żbikowski and Antosiuk, 2021 ; Retterath, 2020 ) , Twitter (Antretter et al., 2019 ) , web data (Sharchilev et al. … the initial funding round. • Search results: For the Perplexity Sonar API , we apply a time filter to return only those search results that originate from a time before the announcement of the initial funding round. Source Data Field Description Value As Of Watchlist Name F The company name. Some time in 2021 Domain F The company web domain. Some time in 2021 Date Added P The date the company was added to the watchlist. Only companies added between January 1, 2021 and Decemb … t cutoff date 1,715 23.4 Remove companies added post–seed announcement 587 18.7 Apply temporal cutoff (before February 28, 2023) 462 22.0 Match with historic Crunchbase snapshot 259 25.1 Table 3: Dataset size and success rate after successive preprocessing steps. The success rate refers to the share labeled successful at the corresponding stage. Appendix B DIALECTIC Design Details B.1 Seed Questions To kick off DIALECTIC’s question decomposition, we provide it with a set of s … gument. We use an LLM judge (Zheng et al., 2023 ) to evaluate each argument and apply the taxonomy of argument quality proposed by Wachsmuth et al. ( 2017 ) . Following the instruction design principles by Wachsmuth et al. ( 2024 ) , we adapt the taxonomy criteria to the VC context. The revised framework explicitly defines the objective of argume
Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation from the FDA for the Treatment of T-Cell Lymphoma | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Dialectic... - Below The Belt Women's Cancer Outreach Facebook Log In Below The Belt Women's Cancer Outreach's Post Below The Belt Women's Cancer Outreach March 12 · Shared with Public Dialectic Therapeutics recently announced the dosing of patients in a clinical trial evaluating DT2216 in combination with Paclitaxel for Platinum-Resistant Ovarian Cancer (PROC). This important milestone marks the beginning of a study led by Drs. Elizabeth Stover, Joyce Lu, and Ursula Matulonis at the Dana-Farber Cancer Institute, a world-renowned team that was instrumental in the last FDA a
Funding » Zheng Laboratory » College of Pharmacy » University of Florida Skip to main content Skip to main menu UF Health University of Florida Zheng Laboratory College of Pharmacy Open Search Open Main Menu Home Research - current page Show submenu for Research Research Overview Publications 2019 Publications 2018 Publications Resources Funding - current page Members Show submenu for Members Members Overview Alumni Openings News & Media Show submenu for News & Media News & Media Overview Lab Announcements Media Coverage Contact Us Research Funding Research Overview Expand Pu
Quantum Enters into Definitive Agreement with Dialectic and Other Lenders to Restructure Term Debt Quantum Corporation (QMCO) Quantum Corporation Menu Products ASSET MANAGEMENT PLATFORM FILE & BLOCK OBJECT TAPE BACKUP APPLIANCES SURVEILLANCE & EDGE SERVICES SEE ALL PRODUCTS Asset Management Platform Agile asset management and workflow orchestration platform that provides powerful asset management, automation, and collaboration tools. CatDV Asset Management Watch CatDV TV File & Block StorNext File System A high-performance file system for high throughput, low latency workloads. StorNex … Backup Appliances Deduplication appliance in support of any backup and restore application. DXi-Series Why Quantum DXi Purpose-Built Appliance? 10 Reasons to Choose Quantum DXi Download Now ESG Technical Validation: Quantum DXi9000 Efficient Data Protection for Modern Data Centers Download the Tech Brief Surveillance A security infrastructure portfolio of NVR recording servers, hyperconverged appliances, video analytics servers, and shared archive storage. VS-HCI Series VS-N … vers, and shared archive storage. VS-HCI Series VS-NVR Series VS2108-A VS1110-A Application Server Edge Storage Capture and ingest vast amounts of sensor data inside a moving vehicle under demanding conditions and then quickly and easily upload data for processing. R-Series Reference Architecture Webinar Learn More About Our Latest Solution for Large-Scale Surveillance Workloads. Register Now! Services With Quantum as your knowledge partner, you can quickly build familiarity … Backup Appliances Deduplication appliance in support of any backup and restore application. DXi-Series Why Quantum DXi Purpose-Built Appliance? 10 Reasons to Choose Quantum DXi Download Now ESG Technical Validation: Quantum DXi9000 Efficient Data Protection for Modern Data Centers Download the Tech Brief Surveillance & Edge Back Surveillance A security infrastructure portfolio of NVR recording servers, hyperconverged appliances, video analytics servers, and shared archiv … vers, and shared archive storage. VS-HCI Series VS-NVR Series VS2108-A VS1110-A Application Server Edge Storage Capture and ingest vast amounts of sensor data inside a moving vehicle under demanding conditions and then quickly and easily upload data for processing. R-Series Reference Architecture Webinar Learn More About Our Latest Solution for L
How dialectical was Stoic dialectic? (Chapter 9) - Ancient Models of Mind Skip to main content Accessibility help Login Alert Cancel Log in × × Discover Content Products and Services Register Log In (0) Cart Logo for Cambridge Core from Cambridge University Press. Click to return to homepage. Search Logo for Cambridge Core from Cambridge University Press. Click to return to homepage. Browse Services Open research Institution Login Search Menu links Browse Subjects Subjects (A-D) Anthropology Archaeology Area Studies Art Chemistry Classical Studies Computer Science Drama, Theatre, Performa … delivered even when you are not connected to wi-fi, but note that service fees apply. Find out more about the Kindle Personal Document Service . How dialectical was Stoic dialectic? By Luca Castagnoli Edited by Andrea Nightingale , Stanford University, California , David Sedley , University of Cambridge Book: Ancient Models of Mind Online publication: 06 December 2010 Chapter DOI: https://doi.org/10.1017/CBO9780511760389.010 Your Kindle email address Please provide your Kind … s Please provide your Kindle email. @free.kindle.com @kindle.com ( service fees apply ) Available formats PDF Please select a format to save. By using this service, you agree that you will only keep content for personal use, and will not openly distribute them via Dropbox, Google Drive or other file sharing services Please confirm that you accept the terms of use. Cancel Save × Save book to Dropbox To save content items to your account, please confirm that you agree to abide
--> Fort Worth Biopharma Actuate Therapeutics Raises $21.7M in Series B Funding » Dallas Innovates Toggle navigation When autocomplete results are available use up and down arrows to review and enter to go to the desired page. Touch device users, explore by touch or with swipe gestures. Business Creative Education Impact Invention Startup About Sponsors Partners When autocomplete results are available use up and down arrows to review and enter to go to the desired page. Touch device users, explore by touch or with swipe gestures. Fort Worth Biopharma Actuate Therapeutics Raises $21.7M in … id it will use the funding to expand its ongoing Phase 1 / 2 clinical trial and fund development programs. by Lance Murray • May 20, 2019 [Illustration: Vitanovski via iStock] by Lance Murray • May 20, 2019 Fort Worth-based Actuate Therapeutics Inc. has announced that it raised $21.7 million in a Series B financing round . Actuate is a private biopharmaceutical company that focuses on developing compounds to be used in the treatment of cancer and inflammatory diseases leading … /2 clinical trial—which it has referred to as “groundbreaking” —and fund development programs. CEO and President Daniel Schmitt said Actuate is quickly advancing the 1801 clinical trial of 9-ING-41 in U.S. adult cancer patients. “The financing allows us to expand the 1801 clinical trial out to our world-leading oncology research institution network in the US and Europe; to initiate Investigator Initiated Trials being developed with our physician/scientist collabor … e. United Way of Metropolitan Dallas Awards $1M in Health Innovation Technology Prize Funding Five local winners received up to $200,000 in funding to activate their solutions throughout North Texas. Mayor Cites New Report at the Fort Worth State of Entrepreneurship: Startups Created Nearly 30K Jobs Mayor Mattie Parker, whose catchphrase is "Go Time," says she coined the term for a reason. Fort Worth is at a pinnacle of possibility, and entrepreneurship is … tion Calendar: Not-to-Miss Events for Innovators in Dallas-Fort Worth Invention Apply Now: Opportunities for North Texas Innovators Invention Patented: Visa’s Offline Cryptographic Payments and More North Texas Inventive Activity Related Articles Calendar: Not-to-Miss Events for Innovators in Dallas-Fort Worth Apply Now: Oppo
EX-10.1 4 d12850dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Execution Version TRANSACTION AGREEMENT by and among QUANTUM CORPORATION, DIALECTIC TECHNOLOGY SPV LLC, OC III LVS XXXIII LP and OC III LVS XL LP Dated as of September 23, 2025 TABLE OF CONTENTS Page Article I THE CLOSING Section 1.1 Closing 3 Section 1.2 Company Closing Deliverables 3 Section 1.3 Dialectic Closing Deliverables 4 &nbs … s Proceeds ”); WHEREAS , the Lenders have agreed to permit the Company to apply $1.2 million of the Signing Excess Proceeds to the payment of an exit fee to PNC Bank, National Association (the “ Revolving Lender ”) in connection with the termination of the Company’s revolving credit facility (the “ Revolving Credit Facility ”) under that certain Amended and Restated Revolving Credit and Security Agreement, dated as of December 27, … exercise of outstanding Company Options. Each Company Option, each Company RSU Award and each Company PSU Award was 6 issued in compliance in all material respects with applicable Law. Other than as set forth in this Section 2.2(c) , as of the close of business on the Reference Date, there is no issued, reserved for issuance, outstanding or authorized stock option, restricted stock unit award, restricted stock award, stock appreciation, phantom stock, profit par … profit participation, or similar right, or compensatory equity or equity-linked award with respect to the Company or any Subsidiary of the Company to which the Company or any Subsidiary of the Company is a party or by which the Company or any Subsidiary of the Company is bound. (d) Section 2.2(d) of the Company Disclosure Letter lists all outstanding warrants to acquire shares of Company Common Stock (the “ Company Warrants ”). All of the Company Warrants: ( … roduce copies, prepare derivative works, disclose, combine with other data, and grant third parties rights, as applicable, to each of the Company-Licensed Data and Personal Data as necessary for the operation of the business of the Company and its Subsidiaries. Each of the Company and its Subsidiaries is, and has been, in compliance with all Cont
8: Steph Ango - Tools for Ampl… - Dialectic - Apple Podcasts Search Home New Top Charts Search February 4, 2025 2hr 49min 8: Steph Ango - Tools for Amplifying Our Light Dialectic Play Steph Ango aka Kepano (Website, X) is a designer, writer, entrepreneur,and toolmaker, best known as the CEO of Obsidian, a powerful and flexible writing and thinking tool. Steph's education is in biology and industrial design, but he is true multi-hyphenate creative, working across mediums including software, hardware, supply chain and packaging, words, wood, furniture, ink, color schemes, open-source systems, vi
%PDF-1.4 1 0 obj > endobj 3 0 obj > endobj 4 0 obj [/Pattern /DeviceRGB] endobj 10 0 obj [0 /XYZ 147.750000 728.250000 0] endobj 11 0 obj > >> endobj 12 0 obj > >> endobj 13 0 obj > endobj 15 0 obj > endobj 14 0 obj > endobj 16 0 obj > endobj 5 0 obj > endobj 19 0 obj > /ExtGState > /Pattern > /Font > /XObject > >> endobj 20 0 obj [ 11 0 R 12 0 R ] endobj 17 0 obj > stream x��]M��8r�ׯȳ���o�0���e����cv�Ƣ�����LQR�)Rd~����ա| #�ԟ���� �6��q��������O�� ^ڦz=��R�~��B�����^�� �����8N�〫z ������K; ����U��?2� @��q� =?�Jř� t)��P��ײujZ$,�8}�����~2�Pu�ZH �LxC���R� ,��^�� ��X���
cccc-20251231 0001662579 2025 FY false http://fasb.org/us-gaap/2025#CollaborativeArrangementMember http://fasb.org/us-gaap/2025#CollaborativeArrangementMember P2D P5Y iso4217:USD xbrli:shares iso4217:USD xbrli:shares cccc:segment cccc:security cccc:period cccc:contract xbrli:pure cccc:target cccc:performanceObligation cccc:protein cccc:developmentCandidate cccc:tradingDay cccc:employee 0001662579 2025-01-01 2025-12-31 0001662579 2025-06-30 0001662579 2026-02-23 0001662579 2025-10-01 2025-12-31 0001662579 2025-12-31 0001662579 2024-12-31 0001662579 2024-01-01 2024-12-31 0001662579 us-gaap:Commo … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes x No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12 … ting cash and cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements; • our ability to identify and develop product candidates for treatment of additional disease indications; • the potential attributes and benefits of our product candidates; • the rate and degree of market acceptance and clinical utility for any product candidates we may develop; • the pricing and reimbursemen … erck KGaA Agreement made an upfront cash payment of $16.0 million and agreed to fund our discovery research efforts. We are eligible to receive approximately $740 million in the aggregate in discovery, regulatory, and commercial milestone payments across the collaboration, plus tiered royalties on net sales. Royalties payable from Merck KGaA to us range from mid-single digit to low-double digit percentages, subject to reductions under certain circumstances as described in the … a Pharma of up to $40.0 million following our receipt of approval of a New Drug Application for CFT8919 from the FDA, with the milestone amount based on the percentage of patients in contemplated clinical trials that were enrolled by Betta Pharma and the line of therapy of the approval. In addition, we have agreed to pay Betta Pharma tiered royal
Controversies in nursing ethics: a historical review Controversies in nursing ethics: a historical review J Adv Nurs . 1992 Sep;17(9):1020-7. doi: 10.1111/j.1365-2648.1992.tb02035.x. Author D P Olsen 1 Affiliation 1 Boston College, Chestnut Hill, MA. PMID: 1401542 DOI: 10.1111/j.1365-2648.1992.tb02035.x Abstract The author critiques the dialectic between justice-based ethics and an ethic of caring from a historical perspective (by analogy with the dialectic between agape and friendship). Justice-based ethics have been problematic for nursing because of the decontextualized approach. The
Reorienting Rhetoric: The Dialectic of List and Story By John D. O'Banion --> Reorienting Rhetoric The Dialectic of List and Story John D. O'Banion $40.95 Paperback Edition ISBN: 978-0-271-02660-2 Add to Cart Customers in Europe, UK, Middle East, and Africa Buy Here CART (0) Search Books Featured Keystone Books Eisenbrauns Graphic Mundi Browse By Subject By Series Catalogs Search --> Ordering Exam Copy Requests Books Staff Journals Browse Pricing and Subscriptions Catalogs Permissions Advertising Ethics and Policies Publishing with PSU Press Staff Unlocked Browse All Newly Unlocked Featur
David Genecov - President and CEO, Co-Founder at Dialectic Therapeutics | The Org Platform Enrich Pricing Log in Sign up Dialectic Therapeutics David Genecov Unverified David Genecov President and CEO, Co-Founder Contact Dr. Genecov is a successful health care entrepreneur and trained as a craniofacial surgeon. He most recently co-founded and served on the Board of AveXis with Mr. Harkey, which was acquired by Novartis for $8.7bn in 201B. AveXis created the first successful therapy for spinal muscular atrophy, now FDA- approved. Along with Mr. Harkey, he co-founded and serves on the board of
%PDF-1.7 %���� 678 0 obj >stream hޜXMo$5���خrٖV��E �doa�a�L4;�ȟ^U��U�v8d��.��x���P��R�'�5��0�t�p�1���)p�� �q�P�� ĮK��Pa���^�Ш`�U�O1tVJ�WƘ�0i)��"���1f�I ��7LX�;&}�1���)�bQ�0B�@.ȓ3��:&@�Q'@�%c䊚prC8�58% w���S�x(� aa�1�"#2LJ�Y��`�� �� �� ��2U8���� ��rA���h}P� d�@f [��m�Zs+7� �, w� ȽI���P@ ���5�R%MX��(5PֲUCV@ȁ*� ����ő�IC ��e��e �G�6��� _�1����T ���B��fԧ~/�Ww�}��G3���WмBFjq���D�S���TT=_�hE�^$���n��V���z����b�x����w �1_�e:~��秧���k��?����_W�a���H�� S ������2���i���� w�j��1]� V��|���_�r��aqY\ 1G�>N��$V�a�����ES$�}C��P��,�!u���;�B … acb4b9fa843 xmp.did:339b5e78-f0b3-3c4e-9da9-6f6b069815c1 default converted from application/x-indesign to application/pdf Adobe InDesign 18.5 (Windows) / 2023-09-19T12:47:57-07:00 application/pdf Adobe PDF Library 17.0 False endstream endobj 361 0 obj > endobj 363 0 obj >/OCGs[365 0 R 366 0 R 613 0 R]>>/OpenAction 364 0 R/Outlines 342 0 R/PageLayout/SinglePage/Pages 357 0 R/StructTreeRoot 394 0 R/Type/Catalog/ViewerPreferences >>> endobj 364 0 obj > endobj 365 0 obj > endobj … W����� .�[b�L��Y��� E%�%\��ʟu�*N�#e�� ��)4�~��MS�87��%+]��i���s���̗By�Vf �RFP�"�[U��lDM�l�x���P�sbq�|��В��M�|2��JaV�]�H����Ka �@�5�l��D�'n�HS��R�⛱�O�N����UN��:ڹ̎3��8SO�SeW�U���-~�^� (r� ��>S�; �B[Ja��m#f�J��vR1*��>��1�R& �=(��pq�zNaꃪ�����;�T�.��M&���:�4 V��}�� Sml'l�k���s�%@�&�E�s}m�l2��|-I"��AQ\ڂ��ud���ĝu>���m"m��.�Q5 &s6P\M�� � B7DEY�bxT���Ѱ�-���R�ˌ�%eC�� �o;aN�Isv��(t�+�I���9��\C� f��Cm�GF˪� ��T����t��� ȷ,j�uD�輖b�c="Ț�f�S}لK�� p���G��M … XipWho endstream endobj 539 0 obj > endobj 540 0 obj > endobj 541 0 obj >stream application/pdf Icon_tag 2015-09-09T15:37:26-04:00 2015-09-09T15:37:26-04:00 2015-08-26T17:30:22-04:00 Adobe Illustrator CS6 (Macintosh) uuid:8558e767-f09e-6f49-b40d-bc8dd3747386 xmp.did:038011740720681180838CD1423AA41D uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:4031dfc9-895c-d744-b95c-6cc9527c11dd xmp.did:F87F117407206811822A90CCB92393E3 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf s
Dialectic Ep. 48: 🏕️ Henri Stern Modern technologists--especially in crypto--are often deeply principled or impressively pragmatic. Henri is both. I talked to Henri about digital privacy, the… | Jackson Dahl LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any ti
Dialectic Therapeutics - Legal and Compliance Team | The Org Platform Enrich Pricing Log in Sign up Dialectic Therapeutics Teams Legal and Compliance Team Unverified Legal and Compliance Team 4 people · 0 jobs The Legal and Compliance Team at Dialectic Therapeutics is responsible for ensuring adherence to regulatory requirements and safeguarding the company's intellectual property. This team manages legal affairs, oversees compliance with healthcare laws, and supports business development initiatives, all while ensuring that Dialectic’s innovative cancer treatments meet the highest ethi
Dialectic Therapeutics Jobs + Careers | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Dialectic Therapeutics Teams Dialectic Therapeutics Save Saved Dallas 5 Total Employees View Website Overview Jobs Offices Is This Your Company? Claim Profile Jobs at Dialectic Therapeutics Let Your Resume Do The Work Upload your resume to be matched with jobs you're a great fit for. Upload Resume Success! We'll use this to further personalize your experience. No jobs to discover at this time. back to overview Jobs at
--> Dialectic Therapeutics Using $3M Grant to Further Cancer Research Toggle navigation When autocomplete results are available use up and down arrows to review and enter to go to the desired page. Touch device users, explore by touch or with swipe gestures. Business Creative Education Impact Invention Startup About Sponsors Partners When autocomplete results are available use up and down arrows to review and enter to go to the desired page. Touch device users, explore by touch or with swipe gestures. Dialectic Therapeutics Plans to Further Cancer Drug Research Using $3M Seed Award Using innov … tartup Dialectic Therapeutics Inc. has announced plans to use a $3 million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT) to further develop its lead product candidate, an anti-cancer drug. Dialectic focuses on creating innovative new technologies to address late-stage difficult cancer diagnoses, according to the company. Dialectic was one of three North Texas startups to receive a $3 million award from CPRIT l … ietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology. Grant expected to speed up clinical evaluation In pre-clinical studies, DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra large, or BCL-XL. This stimulates the cells to “commit suicide or become more susceptible to chemotherapy,” according to a statement. Currently, DT2216 is in the Investigational New Drug-enabling phase for use as a single agent or as part of a … oval to conduct the first-in-human clinical trials with a new drug. “This grant will give us the opportunity to reach clinical relevance faster,” Dr. David Genecov, Dialectic’s president and CEO, said in a statement. “The CPRIT funding will support continued development of our lead candidate, DT2216, which we believe may be a first-in-class anticancer agent targeting BCL-XL, the most commonly over-expressed antiapoptotic protein in cancer.” Diale … Cancer Prevention and Research Institute of Texas (CPRIT) will convert previous grant awards to an equity investment. OncoNano uses pH as a biomarker to detect metastatic cancer. The technology "lights up" a tumor in imaging during real-time surgery. North Texas Innovation Alliance Teams Up to Supersize New Smart City Partnership The NTXIA is a f
Dialectic acquires Outdoor Tech | Outdoor Tech® LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and
%PDF-1.4 %���� 47 0 obj > endobj xref 47 25 0000000016 00000 n 0000001145 00000 n 0000001208 00000 n 0000001351 00000 n 0000001507 00000 n 0000002548 00000 n 0000003570 00000 n 0000004602 00000 n 0000004692 00000 n 0000005716 00000 n 0000006756 00000 n 0000006902 00000 n 0000007096 00000 n 0000008277 00000 n 0000008485 00000 n 0000008683 00000 n 0000010697 00000 n 0000011779 00000 n 0000012045 00000 n 0000041106 00000 n 0000069537 00000 n 0000098427 00000 n 0000106630 00000 n 0000114325 00000 n 0000000796 00000 n trailer ]>> startxref 0 %%EOF 71 0 obj >stream x�b```�hVwA��1�0p�dqo4 … 8-04:00 2008-10-14T12:12:28-04:00 itext-paulo (lowagie.com)[JDK1.1] - build 132 application/pdf uuid:9da4787e-93a8-4972-8588-97565c4c6230 uuid:3d25b4f7-db8d-4575-ab01-4c853f8fe667 endstream endobj 46 0 obj > endobj xref 0 47 0000000000 65535 f 0000114592 00000 n 0000114719 00000 n 0000114821 00000 n 0000117177 00000 n 0000117363 00000 n 0000117549 00000 n 0000117730 00000 n 0000117806 00000 n 0000117934 00000 n 0000118078 00000 n 0000128512 00000 n 0000136822 00000 n 00001370
What The Heck is a Dialectic? - Behavioral Psych Studio Menu Home DBT Center DBT Center - What We Treat Treatments Offered DBT for Adults DBT Center - Adolescents DBT Center - Children & Parents DBT Center - Parents, Families & Couples DBT for Substance Use Disorders Adult Adult - What We Treat Treatments Offered CBT Treatments LGBTQ+ Center IOP Program Child & Adolescent Child/Adolescent What We Treat Treatments Offered CBT Treatments DBT Center - Adolescents DBT Center - Children & Parents LGBTQ+ Center IOP Program About Us Our Team Our Locations New York - Location San D
Dialectic Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Dialectic Therapeutics, Inc. Startups | Private Company | 2018 | Texas, United States | < 10 | www.dtsciences.com Startups | Private Company | 2018 | Texas, United States | < 10 | www.dtsciences.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Hemic and Lymphatic Diseases Other Diseases Proteolysis-targeting chimeras (PROTAC) … the APTaD™ Technology Platform In preclinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces the degradation of B-cell lymphoma extra-large, or BCL-XL, in cancer cells and either stimulates the return of cellular apoptosis or sensitizes the cells to be more susceptible to chemotherapy, and thus cellular destruction. DT2216 has been shown to be effective in various hematologic and solid tumor … a College of Pharmacy. Dialectic has also been supported to date through a Seed Award for Product Development Research from CPRIT and was recently awarded a Texas Company Product Development Research grant from CPRIT for continued clinical development of DT2216. For more information regarding Dialectic, please visit Dialectic is a registered trademark of Dialectic Therapeutics, Inc. Contact: Joshua Sills, EVP of Operations email: [email protected] Collaborate First in Class … of DT2216, our lead APTaD™ compound. This, along with FDA's recent decision to grant orphan drug designation, underscores our belief that DT2216 could be a promising therapeutic for T-cell lymphoma patients" said Dr. David Genecov, Dialectic's President and Chief Executive Officer. "There is a critical unmet need for people diagnosed with this rare cancer, in which current approved therapies have relatively low response rates." Normal T-cells require BCL-XL expression to sur … a College of Pharmacy. Dialectic has also been supported to date through a Seed Award for Product Development Research from CPRIT and a recently awarded Texas Company Product Development Research grant from CPRIT for continued clinical development of DT2216. For more information regarding Dialectic, please visit . Dialectic is a registered tradem
--> Yahoo! Finance: Dialectic Therapeutics announces first-in-human dose in Phase 1 clinical trial evaluating DT2216 - UT Health San Antonio Skip to main content Menu Newsroom UT Health San Antonio Search/Quicklinks Home Education Health Research Community Campus Filter News News Releases Home Education Health Research Community Campus Filter News News Releases Yahoo! Finance: Dialectic Therapeutics announces first-in-human dose in Phase 1 clinical trial evaluating DT2216 Shared By: contributor October 6, 2021 Renowned cancer centers participating in the trial include the Mays Cancer Center at
Reorienting Rhetoric: The Dialectic of List and Story - John D. O'Banion - Google Books Suche Bilder Maps Play YouTube News Gmail Drive Mehr » Anmelden Books Meine Mediathek Hilfe Erweiterte Buchsuche Druckversion Kein E-Book verf�gbar Amazon.de Thalia Buchkatalog.de In einer B�cherei suchen Alle H�ndler » St�bere bei Google Play nach B�chern. St�bere im gr��ten eBookstore der Welt und lies noch heute im Web, auf deinem Tablet, Telefon oder E-Reader. Weiter zu Google Play » Reorienting Rhetoric : The Dialectic of List and Story John D. O'Banion Pennsylvania Stat
Reorienting Rhetoric: The Dialectic of List and Story, by John D. O'Banion | KB Journal Skip to main content KB Journal The Journal of the Kenneth Burke Society Search form Search KB Main menu Home Editorial Board Submissions Issues 16.1 Winter 2023 15.1 Spring 2021 14.1 Summer 2019 13.2 Summer 2018 13.1 Fall 2017 12.2 Spring 2017 11.2 Spring 2016 11.1 Summer 2015 10.1 Summer 2014 9.1 Fall 2013 8.1 Spring 2012 7.2 Spring 2011 7.1 Fall 2010 6.2 Spring 2010 6.1 Fall 2009 5.2 Spring 2009 5.1 Fall 2008 4.2 Spring 2008 4.1 Fall 2007 3.2 Spring 2007 3.1 Fall 2006 2.2 Spring 2006 2.1 Fall 2005 1 … wo ways of thinking, which O'Banion identifies as List and Story (15). In their application, "List records scientific truth, with logic providing tests of a List's accuracy and universality. Story embodies aesthetic 'truth' (meaning), with narration providing guidance in revealing and discovering such situationally bound meaning" (15). As O'Banion sees it (siding with Goody), List has come to be the primary agency of Western logic, science, technology, and "rationality" (11). … the CFP: KB Conference in Ghent 2026 . Proposals are due by October 31st, 2025. Submit to KB Journal Please note! KB Journal is in the process of migrating to a new Drupal 11 website and is temporarily closing the Submittable review system until December 2026. Please check back then! Navigation My Account Shopping cart recent posts search book gallery KB: A Conversation (Video) Find out about Harry Chapin's video interview of Kenneth Burke and how you can get a copy . Shoppin
Making sure you're not a bot! Making sure you're not a bot! Loading... You are seeing this because the administrator of this website has set up Anubis to protect the server against the scourge of AI companies aggressively scraping websites. This can and does cause downtime for the websites, which makes their resources inaccessible for everyone. Anubis is a compromise. Anubis uses a Proof-of-Work scheme in the vein of Hashcash, a proposed proof-of-work scheme for reducing email spam. The idea is that at individual scales the additional load is ignorable, but at mass scraper levels it ad
Reorienting Rhetoric: The Dialectic of List and Story By John D. O'Banion --> Reorienting Rhetoric The Dialectic of List and Story John D. O'Banion $40.95 Paperback Edition ISBN: 978-0-271-02660-2 Add to Cart Customers in Europe, UK, Middle East, and Africa Buy Here CART (0) Search Books Featured Keystone Books Eisenbrauns Graphic Mundi Browse By Subject By Series Catalogs Search --> Ordering Exam Copy Requests Books Staff Journals Browse Pricing and Subscriptions Catalogs Permissions Advertising Ethics and Policies Publishing with PSU Press Staff Unlocked Browse All Newly Unlocked Featur
Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients with Relapsed or Refractory Malignancies Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Foc … the APTaD ™ Technology Platform In preclinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces the degradation of B-cell lymphoma extra-large, or BCL-XL, in cancer cells and either stimulates the return of cellular apoptosis or sensitizes the cells to be more susceptible to chemotherapy, and thus cellular destruction. DT2216 has been shown to be effective in various hematologic and solid t … a College of Pharmacy. Dialectic has also been supported to date through a Seed Award for Product Development Research from CPRIT and was recently awarded a Texas Company Product Development Research grant from CPRIT for continued clinical development of DT2216. For more information regarding Dialectic, please visit www.dtsciences.com. Dialectic is a registered trademark of Dialectic Therapeutics, Inc. Contact: Joshua Sills , EVP of Operations email: [email protecte … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Dialectic Therapeutics Receives $3 Million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Release … Resources Blog Journalists RSS Dialectic Therapeutics Receives $3 Million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas News provided by Dialectic Therapeutics, Inc. Feb 26, 2020, 09:30 ET Share this article Share to X Share this article Share to X DALLAS , Feb. 26, 2020 /PRNewswire/ -- Dialectic Therapeutics, Inc., a Texas -based biotechnology company focused on creating innovative new technologies to end cance … w technologies to end cancer, today announced it has received a $3 million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT). Dialectic will use the funding from the CPRIT Seed Award to further the development of its lead product candidate, DT2216, a unique compound built using its proprietary and novel A ntiapoptotic P rotein T argeted D egradation (APTaD™) technology. In pre-clinical studies, DT2216 selectively … n hematologic cancers. "We are honored and delighted to have received this Seed Award from CPRIT and the state of Texas , and it significantly advances our effort to develop novel drug candidates that address a significant need in cancer treatment. This grant will give us the opportunity to reach clinical relevance faster," said Dr. David Genecov , Dialectic's President and Chief Executive Officer. "The CPRIT funding will support continued development of our lead candidate, D … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS
Dialectic Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors &
Guangrong Zheng PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Guangrong Zheng PhD Director of Medicinal Chemistry & Scientific Co-founder at Dialectic Therapeutics, Inc. Guangrong Zheng PhD 's Executive Work History Current Director of Medicinal Chemistry & Scientific Co-founder , Director of Medicinal
John Harkey Jr. - Chairman of the Board & Co-founder at Dialectic Therapeutics | The Org Platform Enrich Pricing Log in Sign up Dialectic Therapeutics John Harkey Jr. Unverified John Harkey Jr. Chairman of the Board & Co-founder Contact Mr. Harkey is the Founder of JDH Investment Management, LLC, which is focused on leading innovative and impactful opportunities in the biotechnology industry. Notably, he was the Co-founder and Executive Chairman of AveXis, which was acquired by Novartis for $8.7bn in 201B. He currently serves as Co-founder, Board Member and Co-CEO of Cessation Therap
Dialectic Therapeutics, Inc. - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Organization Dialectic Therapeutics, Inc. dtsciences.com Company Details Description Dialectic Therapeutics (DT) is a pre-clinical biotechnology company dedicated to the development of unique, impactful anti-cancer drugs that effectively treat
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC) Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia Al … earch Institute of Texas (CPRIT), including a Seed and Company Product Research grant to support the continued clinical development of DT2216 [DP210005]. Contact: Joshua Sills, Chief Operating Officer Email: [email protected] SOURCE Dialectic Therapeutics, Inc. 21 % more press release views with Request a Demo × Modal title --> Contact PR Newswire Call PR Newswire at 888-776-0942 from 8 AM - 9 PM ET Chat with an Expert Contact Us General Inquiries Editorial Bureaus … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation From the FDA for the Treatment of T-Cell Lymphoma – UF Innovate Skip to content University of Florida Search University of Florida FOR ENTREPRENEURS Accelerate Events Entrepreneurship & More Search Technologies FOR ENTREPRENEURS Accelerate Events Entrepreneurship & More Search Technologies FOR INNOVATORS Report a New Discovery Innovator’s Guide Read UF’s IP Policy FAQ & Resources FOR INNOVATORS Report a New Discovery Innovator’s Guide Read UF’s IP Policy FAQ & Resources Search About News Even … Startups Industry Search Technologies Internships Ventures EIRs Advisory Board Submit Your Pitch Deck Got What It Takes To Be An EIR? Accelerate Apply The Hub Sid Martin Biotech Sponsorship Mentor Program Programs Pathways Get Started Foundational Training NSF I-Corps About I-Corps Benefits of I-Corps Introductory Workshops Regional Course Frequently Asked Questions I-Corps Contacts Development & Translational Support Entrepreneurship & More SBIR and STTR Grant Fun … Startups Industry Search Technologies Internships Ventures EIRs Advisory Board Submit Your Pitch Deck Got What It Takes To Be An EIR? Accelerate Apply The Hub Sid Martin Biotech Sponsorship Mentor Program Programs Pathways Get Started Foundational Training NSF I-Corps About I-Corps Benefits of I-Corps Introductory Workshops Regional Course Frequently Asked Questions I-Corps Contacts Development & Translational Support Entrepreneurship & More SBIR and STTR Grant Fun … Startups Industry Search Technologies Internships Ventures EIRs Advisory Board Submit Your Pitch Deck Got What It Takes To Be An EIR Accelerate Apply The Hub Sid Martin Biotech Sponsorship Mentor Program Programs Collaboratory Pathways Get Started Foundational Training NSF I-Corps (2025 version) Development & Translational Support Entrepreneurship & More SBIR and STTR Grant Funding Mentorship, Collaboration & Outreach UF Research Contact Us For Innovators Repo … Startups Industry Search Technologies Internships Ventures EIRs Advisory Board Submit Your Pitch Deck Got What It Takes To Be An EIR Accelerate Apply The Hub Sid Martin Biotech Sponsorship Mentor Program Programs Collaboratory Pathways Get Started Foundational Training NSF I-Corps (2025 version) Development & Translational Support Entrepren
Dialectic Therapeutics Announces DT2216 Has Received Fast Track Designation from the FDA for Adult Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Comp … of DT2216, our lead APTaD™ compound. This, along with FDA's recent decision to grant orphan drug designation, underscores our belief that DT2216 could be a promising therapeutic for T-cell lymphoma patients" said Dr. David Genecov , Dialectic's President and Chief Executive Officer. "There is a critical unmet need for people diagnosed with this rare cancer, in which current approved therapies have relatively low response rates." Normal T-cells require BCL-XL expression to su … a College of Pharmacy. Dialectic has also been supported to date through a Seed Award for Product Development Research from CPRIT and a recently awarded Texas Company Product Development Research grant from CPRIT for continued clinical development of DT2216. For more information regarding Dialectic, please visit www.dtsciences.com. Dialectic is a registered trademark of Dialectic Therapeutics, Inc. Contact: Joshua Sills , EVP of Operations email: [email protected] S … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Media Coverage » Zheng Laboratory » College of Pharmacy » University of Florida Skip to main content Skip to main menu UF Health University of Florida Zheng Laboratory College of Pharmacy Open Search Open Main Menu Home Research Show submenu for Research Research Overview Publications 2019 Publications 2018 Publications Resources Funding Members Show submenu for Members Members Overview Alumni Openings News & Media - current page Show submenu for News & Media News & Media Overview Lab Announcements Media Coverage - current page Contact Us News & Media Media Coverage News & Me … he Story PR newswire | Feb 2020 Dialectic Therapeutics Receives $3 Million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas Dialectic will use the funding from the CPRIT Seed Award to further the development of its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology. In pre-clinical studies, DT2216 selectively induces canc … 020 Dialectic Therapeutics Plans to Further Cancer Drug Research Using $3M Seed Award Dallas biotech startup Dialectic Therapeutics Inc. has announced plans to use a $3 million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT) to further develop its lead product candidate, an anti-cancer drug. Read the Story AACR Cancer Discovery | Feb 2020 The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation Research … 019 Evading age: Drs. Daohong Zhou and Guangrong Zheng receive $2.5 million NIH grant to study selective elimination of senescent cells The scientific team of Daohong Zhou, Ph.D., a professor of pharmacodynamics, and Guangrong Zheng, Ph.D., an associate professor of medicinal chemistry, have received a five-year, $2.5 million grant from the National Institutes of Health, or NIH, to study selective elimination of senescent cells. Their research has the potential to extend huma
Daohong Zhou - Board Member & Scientific Co-founder at Dialectic Therapeutics | The Org Platform Enrich Pricing Log in Sign up Dialectic Therapeutics Daohong Zhou Unverified Daohong Zhou Board Member & Scientific Co-founder Contact Dr. Zhou is a Professor of Pharmacodynamics at the College of Pharmacy at the University of Florida. He serves as the Associate Director for Translation and Drug Development and the Harry E. Innes Professorship of Cancer Research at the UF Health Cancer Center. Dr. Zhou has published more than 110 peer reviewed scientific articles and book chapters and co-
The Fibrolamellar Cancer Foundation establishes partnership with Dialectic Therapeutics to support new clinical trial - Fibrolamellar Cancer Foundation × New: FCF Assistant We’re testing a new AI assistant to help patients, caregivers, and researchers find information faster. Click the FCF Assistant button in the lower right corner to try it. Look for the button ⤵︎ Skip to content Menu About Us Our Story and Mission Tucker’s Message Executive Committee, Management & Staff Board of Directors Medical and Scientific Advisors Patient and Caregiver Advisors Financial Information News � … cial Information News & Media Announcements Press Releases For Researchers Grant program FLC Biospecimens Disease Models Model Awards FCF bioinformatics platform Menu About Fibro What is Fibrolamellar? Fibrolamellar FAQ’s Faces of Fibrolamellar A Mother’s Story Newly Diagnosed Treatments Introduction Surgery Chemotherapy Targeted Therapy Immunotherapy Interventional Radiology Radiation Palliative Care Research Publication Library Research Perspectives Research Overview F … er trials that include FLC patients Join the Fight Donate Tumor Tissue Become a Grant Reviewer Provide Data for Research Share Your Story Become an Ambassador Volunteer Give Giving Menu About Fibro What is Fibrolamellar? Fibrolamellar FAQ’s Faces of Fibrolamellar A Mother’s Story Newly Diagnosed Treatments Introduction Surgery Chemotherapy Targeted Therapy Immunotherapy Interventional Radiology Radiation Palliative Care Research Publication Library Research Perspectives Resea … er trials that include FLC patients Join the Fight Donate Tumor Tissue Become a Grant Reviewer Provide Data for Research Share Your Story Become an Ambassador Volunteer Give Giving Press Releases Home » Press Releases » The Fibrolamellar Cancer Foundation establishes partnership with Dialectic Therapeutics to support new clinical trial The Fibrolamellar Cancer Foundation establishes partnership with Dialectic Therapeutics to support new clinical trial Effort will support a ne … clinical trial involving fibrolamellar patients. Under the agreement, FCF will fund the production of the DT2216 necessary to support the trial. The Foundation’s funding of the manufacturing costs of the drug was crucial to ensure the launch of the clinical trial this year. DT2216 is Dialectic Therapeutic’s first-in-class anticancer a
🔥 Dialectic steps into the spotlight as a Gold Sponsor of Stable Summit! Dialectic is unlocking real value for its members by solving the toughest ciphers in the financial world. Connect with… | Stable Summit LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any t
Dialectic Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News … Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas News provided by Dialectic Therapeutics Aug 20, 2021, 09:00 ET Share this article Share to X Share this article Share to X DALLAS , Aug. 20, 2021 /PRNewswire/ -- Dialectic Therapeutics, Inc. (Dialectic ® ), a Texas -based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today ann … has received a $14.4 million Texas Company (TXCO) Product Development Research Award from the Cancer Prevention & Research Institute of Texas (CPRIT). Dialectic will use the funding from this grant award to further advance the clinical development of its lead product candidate, DT2216, a unique compound built using its proprietary and novel A ntiapoptotic P rotein Ta rgeted D egradation (APTaD™) technology platform. This grant adds to the initial $3 million Seed Award th … rapy, and thus cellular destruction. "We are honored to have received this TXCO Award from CPRIT and the state of Texas and are grateful for their continued support of Dialectic. This award will support the further development of our lead candidate, DT2216, including conducting a first-in-human phase 1 dose escalation study, initiating phase 2 studies and continued development of our chemistry, manufacturing and controls" said Dr. David Genecov , Dialectic's President and Chi … ialectic is CPRIT's first SEED awardee to successfully compete for a CPRIT TXCO award." About Dialectic Therapeutics Dialectic is a Texas -based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer. Our goal is to relieve the suffering of patients with cancer and prolong their productive lives throu
Dialectic Therapeutics raises more than $6M - Drug Discovery and Development Drug Discovery and Development Home Drug Discovery and Development Drug Discovery Women in Pharma and Biotech Oncology Neurological Disease Infectious Disease Resources Video features Podcast Views Webinars Pharma 50 2026 Pharma 50 2025 Pharma 50 2024 Pharma 50 2023 Pharma 50 2022 Pharma 50 2021 Pharma 50 Advertise SUBSCRIBE Dialectic Therapeutics raises more than $6M By Sean Whooley | February 12, 2021 Dialectic Therapeutics issued an SEC Form D to confirm the sale of nearly $6.4 million in debt, options, warrants an
Quantum Secures Strategic Investment as Dialectic Acquires $51M Debt | QMCO Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks C
MEMORANDUM DECISION GRANTING DIALECTIC DISTRIBUTION LLC’S MOTION FOR SUMMARY JUDGMENT ON ITS SECOND CLAIM FOR RELIEF TO DENY A DISCHARGE TO DAVID CAMEO | Eastern District of New York | United States Bankruptcy Court Skip to main content United States Bankruptcy Court Eastern District of New York Hon. Jil Mazer-Marino, Chief Judge - Paul Dickson, Clerk of Court Search form Search this site Home Court Information About Us Contact Us Emergency and Weather Advisories Case Filing Statistics Frequently Asked Questions Obtaining Copies of Court Records Court Services and Technology Unclaimed Funds In
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
THANK YOU Dialectic Engineering for your amazing support of the 2022 Kidney Walk! Providing sponsorship, forming a walk team, and serving on our leadership council are all ways YOU'RE bringing success to Kidney Walk and making a difference in the kidney community! #kidneywalkict #kidneywalkkc... - National Kidney Foundation - Kansas, Missouri, and Arkansas Facebook Log In National Kidney Foundation - Kansas, Missouri, and Arkansas's Post National Kidney Foundation - Kansas, Missouri, and Arkansas October 13, 2022 · Shared with Public THANK YOU Dialectic Engineering for your amazing s
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Explaining the Life Cycle of Bank-Sponsored Money Market Funds: An Application of the Regulatory Dialectic - Federal Reserve Bank of Kansas City --> Research Agriculture Banking Community Development Education TEN Magazine Jackson Hole Research National Economy Economic Review Economic Bulletin Charting the Economy Research Working Papers Payments System Research Briefings Local Economy Nebraska Economist Oklahoma Economist Rocky Mountain Economist Surveys Agricultural Credit Survey Beige Book Current Population Survey Community Conditions Survey Energy Survey Manufacturing Survey Services Sur … on't miss our newest educational resources to help students understand and apply economics, personal finance and more. TEN Magazine Subscribe here TEN Magazine archive Nebraska Community Faces Uncertainty After Tyson Closure Lexington residents continue to deal with ripple effects after the biggest employer abruptly closed. Jackson Hole Jackson Hole 2025 About the Jackson Hole Economic Policy Symposium History of Jackson Hole Symposium proceedings Jackson Hole FAQs Jacks … on't miss our newest educational resources to help students understand and apply economics, personal finance and more. TEN Magazine TEN Magazine Subscribe here TEN Magazine archive Nebraska Community Faces Uncertainty After Tyson Closure Lexington residents continue to deal with ripple effects after the biggest employer abruptly closed. Jackson Hole Jackson Hole Jackson Hole 2025 About the Jackson Hole Economic Policy Symposium History of Jackson Hole Symposium proceedin … rent Article Explaining the Life Cycle of Bank-Sponsored Money Market Funds: An Application of the Regulatory Dialectic How banks and regulators react to each other helps explain how the money market fund industry has evolved. February 05, 2024 Research Working Paper Banking and Finance Data and Trends Law and Economics Subscribe Share by: Stefan A. Jacewitz , Jonathan Pogach , Haluk Unal and Chengjun Wu Download Article RWP 24-01, February 2024; updated August 2024 In this p … al evidence of the regulatory dialectic in the prime institutional money market fund (PI-MMF) industry. The “regulatory dialectic,” developed by Kane (1977, 1981), describes how banks and regulators react to each other. For decades, a cap on commercial deposit interest rates fueled dramatic growth in bank-sponsored PI-MMFs as a form of shadow ban
Error Facebook Facebook is not available on this browser To continue using Facebook, get one of the browsers below. Learn more English (US) + Meta © 2026
%PDF-1.6 %���� 2582 0 obj > endobj 2605 0 obj >/Filter/FlateDecode/ID[ ]/Index[2582 39]/Info 2581 0 R/Length 111/Prev 1389949/Root 2583 0 R/Size 2621/Type/XRef/W[1 3 1]>>stream h�bbd```b``�"�Iw�z D2/��H&[0)�a��߀�O���`�L2�Ʌ@��1�]bϽb7�����������D�bT#�3��� �,�` endstream endobj startxref 0 %%EOF 2620 0 obj >stream h�b```�U � � B ce`a�����T#$ ZT8Z8� Z��3��Oa}����5@X�ō���=@[�ۚ��� ��C����L� � ��f0i;xM��`UbR w?�(p ����2 $�s�>�c��1"d�&�L96�G�� %�OяJjT7t��( ��:��G���eҹ��,A�9�s\sD1���FY�#]��U?\� g(��8�$����Q�D�!#��'�~� H�~( �2cGG�� `�آ��!(��� �a … 616d85f-b7d3-4ea4-875a-dd0747eaa52a uuid:5ce6487f-91b9-4ba6-a843-eea9599d4e19 1 application/pdf Adobe PDF Library 23.8.234 D:20240730211800 true 2023-10-05T20:29:54Z Privileged 65269c60-0483-4c57-9e8c-3779d6900235 b397c653-5b19-463f-b9fc-af658ded9128 9b9e6a80-09a7-42e2-ba3b-dbbf1b3f8a7d 0 true 2023-10-06T13:31:54Z Privileged None 26c83bc9-31c1-4d77-a523-0816095aba31 ae08221f-d8f6-445a-899c-3ab33acf08cd 0 endstream endobj 156 0 obj >stream hޜ��NC1 E��b'v����RUlC%� �k�� … 616d85f-b7d3-4ea4-875a-dd0747eaa52a uuid:b92f7269-2e21-490b-be5b-e2c9a3023bae 1 application/pdf Adobe PDF Library 23.8.234 D:20240730211800 true 2023-10-05T20:29:54Z Privileged 65269c60-0483-4c57-9e8c-3779d6900235 b397c653-5b19-463f-b9fc-af658ded9128 9b9e6a80-09a7-42e2-ba3b-dbbf1b3f8a7d 0 true 2023-10-06T13:31:54Z Privileged None 26c83bc9-31c1-4d77-a523-0816095aba31 ae08221f-d8f6-445a-899c-3ab33acf08cd 0 endstream endobj 2621 0 obj > endobj 2622 0 obj > endobj 2623 0 obj > en … 616d85f-b7d3-4ea4-875a-dd0747eaa52a uuid:fe1121b7-2e01-4aa8-8ad9-e569f87008e9 1 application/pdf Explaining the Life Cycle of Bank-Sponsored Money Market Funds: An Application of the Regulatory Dialectic Explaining the Life Cycle of Bank-Sponsored Money Market Funds: An Application of the Regulatory Dialectic FDIC bank bank holding company bank run financial crisis liquidity risk money market fund systemic risk too big to fail Adobe PDF Library 23.8.234 bank, bank holding comp … bank holding company, bank run, financial crisis, liquidity risk, money market fund, systemic risk, too big to fail D:20240730211800 true 2023-10-05T20:29:54Z Privileged 65269c60-0483-4c57-9e8c-3779d6900235 b397c653-5b19-463f-b9fc-af658ded9128 9b9e6a80-09a7-42e2-ba3b-dbbf1b3f8a7d 0 true 2023-10-06T13:31:54Z Privileged None 26c83bc9-31c1-4d77-a52
The Fibrolamellar Cancer Foundation Establishes Partnership With Dialectic Therapeutics – UF Innovate Skip to content University of Florida Search University of Florida FOR ENTREPRENEURS Accelerate Events Entrepreneurship & More Search Technologies FOR ENTREPRENEURS Accelerate Events Entrepreneurship & More Search Technologies FOR INNOVATORS Report a New Discovery Innovator’s Guide Read UF’s IP Policy FAQ & Resources FOR INNOVATORS Report a New Discovery Innovator’s Guide Read UF’s IP Policy FAQ & Resources Search About News Events Tech Tuesday Tech Tuesday Interest F … Startups Industry Search Technologies Internships Ventures EIRs Advisory Board Submit Your Pitch Deck Got What It Takes To Be An EIR? Accelerate Apply The Hub Sid Martin Biotech Sponsorship Mentor Program Programs Pathways Get Started Foundational Training NSF I-Corps About I-Corps Benefits of I-Corps Introductory Workshops Regional Course Frequently Asked Questions I-Corps Contacts Development & Translational Support Entrepreneurship & More SBIR and STTR Grant Fun … Startups Industry Search Technologies Internships Ventures EIRs Advisory Board Submit Your Pitch Deck Got What It Takes To Be An EIR? Accelerate Apply The Hub Sid Martin Biotech Sponsorship Mentor Program Programs Pathways Get Started Foundational Training NSF I-Corps About I-Corps Benefits of I-Corps Introductory Workshops Regional Course Frequently Asked Questions I-Corps Contacts Development & Translational Support Entrepreneurship & More SBIR and STTR Grant Fun … Startups Industry Search Technologies Internships Ventures EIRs Advisory Board Submit Your Pitch Deck Got What It Takes To Be An EIR Accelerate Apply The Hub Sid Martin Biotech Sponsorship Mentor Program Programs Collaboratory Pathways Get Started Foundational Training NSF I-Corps (2025 version) Development & Translational Support Entrepreneurship & More SBIR and STTR Grant Funding Mentorship, Collaboration & Outreach UF Research Contact Us For Innovators Repo … Startups Industry Search Technologies Internships Ventures EIRs Advisory Board Submit Your Pitch Deck Got What It Takes To Be An EIR Accelerate Apply The Hub Sid Martin Biotech Sponsorship Mentor Program Programs Collaboratory Pathways Get Started Foundational Training NSF I-Corps (2025 version) Development & Translational Support Entrepren
Dialectic Therapeutics Announces DT2216 Has Received Fast Track Designation from the FDA for Adult Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Searc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Dialectic Therapeutics Announces DT2216 Has Received Fast Track Designation from the FDA for Adult Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma April 5, 2022 | 4 min read Twitter LinkedIn Facebook Email Print Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based clinical … of DT2216, our lead APTaD™ compound. This, along with FDA's recent decision to grant orphan drug designation, underscores our belief that DT2216 could be a promising therapeutic for T-cell lymphoma patients" said Dr. David Genecov , Dialectic's President and Chief Executive Officer. "There is a critical unmet need for people diagnosed with this rare cancer, in which current approved therapies have relatively low response rates." Normal T-cells require BCL-XL expression to su … a College of Pharmacy. Dialectic has also been supported to date through a Seed Award for Product Development Research from CPRIT and a recently awarded Texas Company Product Development Research grant from CPRIT for continued clinical development of DT2216. For more information regarding Dialectic, please visit www.dtsciences.com. Dialectic is a registered trademark of Dialectic Therapeutics, Inc. Contact: Joshua Sills , EVP of Operations email: [email protected] View … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufac … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216 March 3, 2021 | 2 min read Twitter LinkedIn Facebook Email Print Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based biotechnology company focused on creating i … gradation (APTaD™) technology. In pre-clinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy. "FDA clearance of our IND represents an important milestone as it transitions Dialectic into a clinical-stage company and further advances us toward … the pre-clinical development of DT2216 have also been supported through a Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT). For more information regarding Dialectic, please visit www.dtsciences.com. Dialectic is a registered trademark of Dialectic Therapeutics, Inc. Contact: Josh Sills , EVP of Operations email: [email protected] View original content: http://www.prnewswire.com/news-releases/dialec … newswire.com/news-releases/dialectic-therapeutics-receives-fda-clearance-of-ind-application-for-lead-antiapoptotic-protein-targeted-degradation-aptad-candidate-dt2216-301239168.html SOURCE Dialectic Therapeutics Twitter LinkedIn Facebook Email Print LATEST ADC Therapeutics ADC Therapeutics lays off 17% of global workforce June 26, 2026 &nb
Dialectic Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developme … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Dialectic Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas August 20, 2021 | 3 min read Twitter LinkedIn Facebook Email Print Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based clinical stage biotechnolog … has received a $14.4 million Texas Company (TXCO) Product Development Research Award from the Cancer Prevention & Research Institute of Texas (CPRIT). DALLAS , Aug. 20, 2021 /PRNewswire/ -- Dialectic Therapeutics, Inc. (Dialectic ® ), a Texas -based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced it has received a $14.4 million Texas Company (TXCO) Product Development Research Award from the Can … ; Research Institute of Texas (CPRIT). Dialectic will use the funding from this grant award to further advance the clinical development of its lead product candidate, DT2216, a unique compound built using its proprietary and novel A ntiapoptotic P rotein Ta rgeted D egradation (APTaD™) technology platform. This grant adds to the initial $3 million Seed Award that Dialectic received from CPRIT in 2020, which was instrumental in supporting preclinical studies. These studies dem … rapy, and thus cellular destruction. "We are honored to have received this TXCO Award from CPRIT and the state of Texas and are grateful for their continued support of Dialectic. This award will support the further development of our lead candidate, DT2216, including conducting a first-in-human phase 1 dose escalation study, initiating phase 2 st
Dialectic About Science & Technology Our Team Resources Contact About Science & Technology Our Team Resources Contact INNOVATIVE THERAPIES REPROGRAMMING CANCER CELL DEATH INNOVATIVE THERAPIES REPROGRAMMING CANCER CELL DEATH Dialectic Therapeutics’ mission is to create innovative new technologies to treat cancer. Our goal is to relieve the suffering of patients with cancer, to give them hope and prolong their productive lives through targeted therapies with limited toxicities and complications. Dialectic Therapeutics is a biotechnology company dedicated to the development of unique … te the safety and efficacy of their investigational drug in clinical trials and submit trial results to regulatory agencies. To participate in a trial, you must meet certain criteria. For those patients that meet the criteria of a clinical trial, participation comes with certain risks and these risks need to be discussed with your doctor. Our lead product DT2216 is currently being investigated in a Phase 1 clinical trial. To learn more, visit www.clinicaltrials.gov. Expanded … patient has exhausted all available treatment options, regulatory agencies may grant permission for a company to provide a doctor with an investigation drug prior to its approval. This use of an investigational drug pre-approval is often referred to as expanded access but may be referred to by other names depending upon the regulatory agency. Dialectic is currently in Phase 1b/2 trials and is not eligible to provide access to investigational drug through expanded access at t … Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas DALLAS, Aug. 20, 2021 /PRNewswire/ — Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced it has received a $14.4 million Texas Company (TXCO) Product Development Research Award from the Cancer Prevention … ; Research Institute of Texas (CPRIT). Dialectic will use the funding from this grant award to further advance the clinical development of its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology platform. 03.03.2021 PRNewswire Dialectic Thera
Closing the Sponsorship Gap for Underrepresented Talent | Dialectic posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t … ze rest, and prevent burnout without starting from zero every month. The Rooted Residency™ This is my passion project. It is a values-driven framework for organizations where I provide high-impact Content Strategy Project Management and Facilitation. The program operates on a mixed compensation model, utilizing both paid compensation and flexible work exchange/time-banking models to ensure accessibility and mutual benefit. See the 2nd comment for the program overview. Learn m … reusing old materials to protect rest and prevent burnout. 🫱🏿🫲🏾 The Rooted Residency™: A values-driven, reciprocal model for organizations focused on equity and sustainability to engage Yolanda's high-impact skills. If you are ready to move from digital overwhelm to "Virgo Precision™" while centering your own capacity for rest, Yolanda is the partner you need. 👉 Reach out to Yolanda via DM or check out her resources: Links in Comments! 💡 This post is part of Brave Spac
Partnership with Dialectic Therapeutics enables launch of clinical trial - Fibrolamellar Cancer Foundation × New: FCF Assistant We’re testing a new AI assistant to help patients, caregivers, and researchers find information faster. Click the FCF Assistant button in the lower right corner to try it. Look for the button ⤵︎ Skip to content Menu About Us Our Story and Mission Tucker’s Message Executive Committee, Management & Staff Board of Directors Medical and Scientific Advisors Patient and Caregiver Advisors Financial Information News & Media Announcements Press Releases For Re … cial Information News & Media Announcements Press Releases For Researchers Grant program FLC Biospecimens Disease Models Model Awards FCF bioinformatics platform Menu About Fibro What is Fibrolamellar? Fibrolamellar FAQ’s Faces of Fibrolamellar A Mother’s Story Newly Diagnosed Treatments Introduction Surgery Chemotherapy Targeted Therapy Immunotherapy Interventional Radiology Radiation Palliative Care Research Publication Library Research Perspectives Research Overview F … er trials that include FLC patients Join the Fight Donate Tumor Tissue Become a Grant Reviewer Provide Data for Research Share Your Story Become an Ambassador Volunteer Give Giving Menu About Fibro What is Fibrolamellar? Fibrolamellar FAQ’s Faces of Fibrolamellar A Mother’s Story Newly Diagnosed Treatments Introduction Surgery Chemotherapy Targeted Therapy Immunotherapy Interventional Radiology Radiation Palliative Care Research Publication Library Research Perspectives Resea … er trials that include FLC patients Join the Fight Donate Tumor Tissue Become a Grant Reviewer Provide Data for Research Share Your Story Become an Ambassador Volunteer Give Giving Announcements Home » Partnership with Dialectic Therapeutics enables launch of clinical trial Partnership with Dialectic Therapeutics enables launch of clinical trial April 18, 2025 April 18, 2025 FCF is pleased to announce its partnership with Dialectic Therapeutics to supply an experimental drug, … lanned clinical trial for fibrolamellar patients. Under the agreement, FCF will fund the production of the DT2216 necessary to support the trial. The Foundation’s funding of the manufacturing costs of the drug was crucial to ensure the timely launch of the clinical trial this year. Dialectic Therapeutics, Inc. is a Texas-based clinical
Episode 10 of Dialectic Podcast with Josh Wolfe is out now. Josh is what you’d get if you combined a macro investor’s slow-thinking wisdom, a culture junky’s encyclopedic memory, a performer’s… | Jackson Dahl LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any ti
Dialectic | UCLA Law Review About Contact Us Masthead Volume 74 Masthead Past Mastheads Membership Subscriptions Our Values Sponsorship Scholarship Print Discourse Dialectic Submissions Scholars Students Discourse Symposium Bluesky Instagram Linkedin Search Category Dialectic di·a·lec·tic /dī-ə-ˈlek-tik/ ·n. The art of investigating the truth of opinions; testing of truth by discussion. On Dialectic, we invite our authors, as well as other legal scholars and professionals, to comment on topical issues raised by the UCLA Law Review publications. The podcast format allows us to offer in-depth in … ilblazers at the intersection of creativity and advocacy. Tim Friedlander is an award-winning voice actor and the President and Co-Founder of the National Association of Voice Actors. Avi Gandhi is the Founder of Creator Logic, a content creator, and a pioneer in the field of creator representation. Tim and Avi discuss how the rise of social media platforms... April 2, 2026 Episode 10.2 - The Autocratic Legal Playbook with Professor Scott Cummings In Dialectic April 2, 2026 0 … lume 74 Masthead Past Mastheads Membership Subscriptions Our Values Sponsorship Scholarship Print Discourse Dialectic Submissions Scholars Students Discourse Symposium Search
30. David Senra - The Clarity of Commitment — Dialectic Jackson Dahl Writing Dialectic 30. David Senra - The Clarity of Commitment 09/20/25 · Creator Dialectic Episode 30: David Senra - The Clarity of Commitment - is available on Spotify , Apple Podcasts , and YouTube , and all podcast platforms. Description David Senra ( Website , X ) is a podcaster and loves that title more than anyone. He hosts Founders , where he teaches the lessons of history's greatest entrepreneurs by way of the biographies he reads of them. This week, he launched a second show, David Senra , where he talks to the great … I don't want to think about anything else. People tell me, "You should raise a fund. You should do all this other stuff." No, I will keep podcasting, thank you very much. You're not going to distract me, because I know that 99% of the people on the planet cannot focus on a single thing for a long period of time. That's why 99% will never be great at what they do. It is very important for me to be really great at what I do, if not the best in the world at what I do. Jackson: … the hard way is the right way. This is not intelligence; this is effort. If you apply considerably more effort over a longer period of time, by human nature, you will have less competition. I'm sure there is another me out there. I'm sure there are probably ten. Are there a thousand? Unlikely. So if there are ten of them and there was a competitive game going on... Jackson: We'll share the prizes. It's 10%. David: I have a 10% chance. The odds are way better in my favor than … t other people do, but sometimes I forget the audience. A friend of mine runs a fund, and his thesis is backing second-time founders. I don't do many speaking gigs—it has to be convenient for me or for a friend. This one was in Miami, so I could drive to it, and I'm friends with them. I went up on stage and talked about how stupid it is to sell your company. When people walk up to me now and say, "I sold my company," I say, "Sorry to hear that." My friend said, "You know who' … and carry them with you. Jackson: Creating internal memes. David: Then you can apply them as these situations come up. This is something that Daniel Ek told me. He's ridiculous. He the only company with more paid subscribers than Spotify is Netflix. It's crazy the business he has built, and to me, he's still vastly underrated. Jackson: And there
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC) November 20, 2025 | 4 min read Twitter LinkedIn Facebook Email Print DALLAS , Nov. 19, 2025 /PRNewswire/ -- Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative a … earch Institute of Texas (CPRIT), including a Seed and Company Product Research grant to support the continued clinical development of DT2216 [DP210005]. Contact: Joshua Sills, Chief Operating Officer Email: [email protected] View original content: https://www.prnewswire.com/news-releases/dialectic-therapeutics-announces-dosing-of-first-patient-in-platinum-resistant-ovarian-cancer-proc-302620497.html SOURCE Dialectic Therapeutics, Inc. Twitter LinkedIn Facebook Email Print … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Sequoia Capital's Andrew Reed on Investing Discipline | Dialectic Podcast posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y … - How LP dynamics shape every investment decision - Why founders who understand fund math raise capital faster - The real alignment (and constraints) between founders and investors If you're a founder trying to raise from VCs or someone who wants to become a VC, this is essential listening. ____________ Thanks for our Episode Partner, donna , for making this episode possible. Find elite executive assistants with Donna (links below). https://lnkd.in/edE5s7Vc …more The Untold T … mo Report this post A straightforward question for founders & VCs: When you apply for funding, how much clear and transparent information do VCs actually share? Do they tell you the real timeline, required documents, preparation time and actual cost involved? Or do founders figure it out only after entering the process? I’d love to hear honest experiences from founders, VC partners and people working inside VC firms. 💬 How transparent is the funding process—really? #bizv … rtunity feel urgent? Does it feel inevitable? Does it feel organized? Investors fund momentum. If you're preparing for a raise in the next 6–12 months, now is the time to refine positioning. We often have exploratory calls with founders before they formally launch. 4 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Daniel Glazer 3mo Edited Report this post For UK/EU tech companies looking to raise capital from US VC investors 🇬🇧🇪🇺🇺🇸 Really e
Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation from the FDA for the Treatment of T-Cell Lymphoma Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia … e in the development of DT2216, our lead APTaD™ compound. The FDA's decision to grant orphan drug designation underscores our belief that DT2216 could be a promising therapeutic for T-cell lymphoma patients" said Dr. David Genecov , Dialectic's President and Chief Executive Officer. "There is a critical unmet need for people diagnosed with this rare cancer, in which current approved therapies have relatively low response rates". Normal T-cells require BCL-XL expression to sur … a College of Pharmacy. Dialectic has also been supported to date through a Seed Award for Product Development Research from CPRIT and a recently awarded Texas Company Product Development Research grant from CPRIT for continued clinical development of DT2216. For more information regarding Dialectic, please visit www.dtsciences.com. Dialectic is a registered trademark of Dialectic Therapeutics, Inc. Contact: Joshua Sills , EVP of Operations email: [email protected] S … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Dialectic About Science & Technology Our Team Resources Contact About Science & Technology Our Team Resources Contact INNOVATIVE THERAPIES REPROGRAMMING CANCER CELL DEATH INNOVATIVE THERAPIES REPROGRAMMING CANCER CELL DEATH Dialectic Therapeutics’ mission is to create innovative new technologies to treat cancer. Our goal is to relieve the suffering of patients with cancer, to give them hope and prolong their productive lives through targeted therapies with limited toxicities and complications. Dialectic Therapeutics is a biotechnology company dedicated to the development of unique … te the safety and efficacy of their investigational drug in clinical trials and submit trial results to regulatory agencies. To participate in a trial, you must meet certain criteria. For those patients that meet the criteria of a clinical trial, participation comes with certain risks and these risks need to be discussed with your doctor. Our lead product DT2216 is currently being investigated in a Phase 1 clinical trial. To learn more, visit www.clinicaltrials.gov. Expanded … patient has exhausted all available treatment options, regulatory agencies may grant permission for a company to provide a doctor with an investigation drug prior to its approval. This use of an investigational drug pre-approval is often referred to as expanded access but may be referred to by other names depending upon the regulatory agency. Dialectic is currently in Phase 1b/2 trials and is not eligible to provide access to investigational drug through expanded access at t … Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas DALLAS, Aug. 20, 2021 /PRNewswire/ — Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced it has received a $14.4 million Texas Company (TXCO) Product Development Research Award from the Cancer Prevention … ; Research Institute of Texas (CPRIT). Dialectic will use the funding from this grant award to further advance the clinical development of its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology platform. 03.03.2021 PRNewswire Dialectic Thera